Mineralys Therapeutics, Inc. Common Stock (MLYS NASDAQ) stock market data APIs
$15.3424
0(0%)
as of November 13, 2026
Try our APIs with
free plan!
Mineralys Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Prev. Close
15.3424
Open
15.3459
High
15.3459
Low
14.7273
52 wk Range
14.78-45.615
Market Cap
1 358 M
Shares Outstanding
88 557 K
EPS
-0.64
Beta
0.825
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Mineralys Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Mineralys Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Mineralys Therapeutics, Inc. Common Stock Fundamental Data
Mineralys Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -389 716 992
- Earnings Per Share: -4
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Mineralys Therapeutics, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-11-04
- EPS/Forecast: -0.53
Get Mineralys Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mineralys Therapeutics, Inc. Common Stock News
New
Mineralys outlines December 22 PDUFA timeline while funding lorundrostat launch into 2028
Earnings Call Insights: Mineralys Therapeutics (MLYS) Q3 2026 MANAGEMENT VIEW * "We are now just weeks away from our PDUFA target date of December 22." (President, CEO & Director Jon Congleton) ...
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
Mineralys Therapeutics, Inc. In the large, pivotal Phase 3 Launch-HTN trial, lorundrostat achieved similar significant blood pressure reductions in participants with and without CKD, with consistent ...
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Mineralys Therapeutics, Inc. RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hyperte...
Mineralys Therapeutics, Inc. Q2 2026 Earnings Call Summary
Mineralys Therapeutics, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Positioning and Clinical Differentiation Our analysts just identified a stock with the potential to be the next Nvidia. Te...
Get Mineralys Therapeutics, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.